Campone, Mario
Bidard, François-Clément
Neven, Patrick
Wang, Lei
Ling, Bin
Dong, Yvonne
Paux, Gautier
Herold, Christina
De Giorgi, Ugo
Clinical trials referenced in this document:
Documents that mention this clinical trial
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer
https://doi.org/10.1186/s13058-023-01740-2
Funding for this research was provided by:
Sanofi
Article History
Received: 4 April 2023
Accepted: 6 November 2023
First Online: 10 November 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, applicable International Conference on Harmonisation Good Clinical Practice Guidelines, and applicable laws and regulations. All study participants provided voluntary written informed consent to participate.
: Not applicable.
: MC has received honoraria from GT1, Eli Lilly, and Novartis; has been a consultant for AbbVie, Accord Healthcare, Amgen, AstraZeneca/MedImmune, Daiichi Sankyo Europe GmbH, Gilead, GSK, Lilly, Menarini, MSD, Novartis, Pfizer, Pierre Fabre, Sandoz-Novartis, Sanofi, Seagen, Seattle Genetics, and Servier; has been part of a speakers bureau for Amgen, Lilly, and Novartis; has received research grant/funding (institution) from Novartis; has received travel/accommodation/expense funds from AstraZeneca, Novartis, and Pfizer; and reports other relationships with Roche. F-CB has received payment or honoraria for lectures, presentations, or speakers bureaus from AstraZeneca, General Electric Health, Lilly, Menarini, Pfizer, Roche, and Sanofi; has participated on a data safety monitoring board or advisory board for AstraZeneca, General Electric Health, Lilly, Menarini, Pfizer, and Roche. PN reports nothing to disclose. UDG has received consulting fees from Astellas, AstraZeneca, Bayer, BMS, Ipsen, Janssen, Merck, MSD, Novartis, PharmaMar, Pfizer, and Roche. BL, GP, LW, and YD are employees of Sanofi and may hold shares and/or stock options in the company. CH was an employee of Sanofi at the time this study was conducted.